

3C
JCWSCS 0-6 FEB 2004

FEB-05-2004 17:47

NOVARTIS INTELLECT PROP

FILE COPY

973 781 8064

P.01

Norbert Gruenfeld
Patent Consultant

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover NJ 07936-1080



Tel (862) 778-7853
Fax (973) 781-8064
Internet: norbert.gruenfeld
@group.novartis.com

Fax

Attention Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner of Patents and Trademarks
Washington, DC

Fax no. (703)746-9195

Number of pages including cover page

Date February 5, 2004

Concerning Case 4-30195E - Application No. 10/694,672

Please find enclosed a Letter Correcting Official Filing Receipt with an attached Preliminary Amendment and a corrected Application Data Sheet.

Please handle this matter as quickly as possible. Thank you your help in this matter.

Very truly yours,

Dolores DeCarminé for Norbert Gruenfeld

NG: dd

CONFIDENTIALITY NOTICE

THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVILEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENT(S). IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENT OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE PHONE NUMBERS SET FORTH ABOVE AND DESTROY THIS FAX IMMEDIATELY.

CASE 4-30195E

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Dolores DeCarminé
Type or print name

Dolores DeCarminé
Signature

2/5/2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

ALTMANN ET AL.

Examiner: D. Lambkin (parent application)

APPLICATION NO: 10/694,672

FILED: OCTOBER 28, 2003

FOR: DIPEPTIDE NITRILES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the "Domestic Priority data as claimed by applicant" section as having an inconsistency with PTO records, which is indicated by asterisks.

A review of the file of the instant application uncovered the fact that a clerical error had been made by Applicants at the time of filing in the **Application Data Sheet** under the **Continuity Information** and in the **Preliminary Amendment**. The parent application should read: Application No. **10/342,872**, not Application No. **10/342,372**. It is further noted that the filing receipt for the instant application lists the **filing date** for the parent incorrectly. The correct filing date should read: **01/15/2003**. Applicants believe that the error on the Data Sheet and the Preliminary Amendment caused the inconsistency.

Please issue a corrected filing receipt deleting the line "(*) Data inconsistent with PTO records" and making the needed changes as listed below:

– Domestic Priority data as claimed by applicant

This application is a CON of 10/342,872 01/15/2003
which is a CON of 10/054,590 01/22/2002 ABN
which is a CON of 09/643,639 08/22/2000 PAT 6,353,017
which is a CON of 09/186,223 11/04/1998 ABN
which claims benefit of 60/108,160 12/05/1997 ABN --

A copy of the filing receipt with the correction noted is enclosed.

A new corrected Application Data Sheet and Preliminary Amendment amending the Specification are enclosed herewith, which Applicants request be made of record.

In connection with the correction, it is respectfully requested that the above-identified application be deleted in the "Child Continuity data" of Application No. 10/342,372 to which the instant application is not related.


Please also note that the parent application was examined in Art Unit 1628, Art Unit 1613 is indicated on the present Filing Receipt of the instant application, and it is respectfully requested that the application be directed to the appropriate Art Unit.

Applicants believe the above-noted error is ascribable to Applicants. Accordingly, the Commissioner is hereby authorized to charge the \$25 fee under 37 CFR §1.19(h) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
NG/pk
Encls.: copy of filing receipt
Corrected Application Data Sheet
Preliminary Amendment

Date: February 5, 2004



Norbert Gruenfeld
Agent for Applicants
Reg. No. 30,081
(862) 778-7853



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22312-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/694,672	10/28/2003	1613	856	4-30195E		20	4

CONFIRMATION NO. 4244

001095

THOMAS HOXIE

NOVARTIS, CORPORATE INTELLECTUAL PROPERTY

ONE HEALTH PLAZA 430/2

EAST HANOVER, NJ 07936-1080

FILING RECEIPT



OC000000011778851


NG

Date Mailed: 01/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Eva Altmann, Reinach, SWITZERLAND;
Claudia Betschart, Takarazuka, JAPAN;
Keigo Gohda, Hyogo, JAPAN;
Miyuki Horiuchi, Kobe, JAPAN;
Rene Lattmann, Binningen, SWITZERLAND;
Martin Missbach, Gipf-Oberfrick, SWITZERLAND;
Junichi Sakaki, Hyogo, JAPAN;
Michihiro Takai, Ibaraki, JAPAN;
Naoki Teno, Kobe, JAPAN;
Scott Douglas Cowen, Branchburg, NJ;
Paul David Greenspan, New Providence, NJ;
Leslie Wighton McQuire, Warren, NJ;
Ruben Alberto Tommasi, Whitehouse Station, NJ;
John Henry van Duzer, Asbury, NJ;



Domestic Priority data as claimed by applicant

10/342,872
10/15/2003

This application is a CON of 10/342,872 01/13/2003 *
which is a CON of 10/054,690 01/22/2002 ABN
which is a CON of 09/643,639 08/22/2000 PAT 6,353,017
which is a CON of 09/186,223 11/04/1998 ABN
which claims benefit of 60/108,160 12/05/1997 ABN
(*Data provided by applicant is not consistent with PTO records. ← delete

Foreign Applications

UNITED KINGDOM 9723407.4 11/05/1997

If Required, Foreign Filing License Granted: 01/28/2004

Projected Publication Date: 05/06/2004

Non-Publication Request: No

Early Publication Request: No

Title

Dipeptide derivatives

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

50

Auto-Reply Facsimile Transmission



TO:

Fax Sender at 973 781 8064

Fax Information

Date Received:

Total Pages:

2/5/2004 5:47:28 PM [Eastern Standard Time]
12 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page

2/5/04

Please cancel
one of these
pages which
were sent
inadvertently
in duplicate.

DD

of pages (2)

FEB-05-2004 17:55	NOVARTIS INTELLECT PROP	973 781 8064 P.01
NOVARTIS		Novartis Corporate Intellectual Property One Market Plaza, Rm 400 East Hanover NJ 07930-1080 Tel (973) 776-7523 Fax (973) 781-8064 Internet: ip.intel@novartis.com @novartis.com
Fax		
Address	Office of Initial Patent Examination's Filing Receipt Corrections Committee of Patents and Trademarks Washington, DC (703) 744-9195	
Fax no.	(703) 744-9195	
Number of pages	including cover page	
Date	February 5, 2004	
Concerning	Case 4-30129E - Application No. 10/694,672	
Please find enclosed a Letter Correcting Official Filing Receipt with an attached Preliminary Amendment and a corrected Application Data Sheet.		
Please handle this matter as quickly as possible. Thank you for your help in this matter.		
Very truly yours, Dolores DeCarmin Dolores DeCarmin for Norbert Grunwald		
ENCLOSURE		
<small> This fax contains confidential information which may be proprietary and is intended solely for the use of the addressee. If you are not the intended recipient, please do not print, copy, retransmit, or otherwise use this information. If you have received this fax in error, please notify the sender immediately by telephone or email. The sender will delete the information from its system and will attempt to notify the intended recipient. If you are the intended recipient, please delete this information from your system after use. If you are not the intended recipient, please notify the sender immediately by telephone or email. The sender will delete the information from its system and will attempt to notify the intended recipient. If you are the intended recipient, please delete this information from your system after use. </small>		
PAGE 1/2 * RCVD AT 2/5/2004 18:07:20 PM [Eastern Standard Time] * SVR:USPTO-EF-XRF-2/3 * DNIS:7469195 * CSID:973 781 8064 * DURATION (mm-ss):00-56		

